CX08005 | CAS#1256341-22-6 | PTP1B/TCPTP inhibitor

MedKoo Cat#: 563748 | Name: CX08005

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CX08005 is a small-molecule compound designed as a selective inhibitor of kinase activity, targeting aberrant signaling pathways in cancer cell lines. It exhibits high binding affinity to its target protein, demonstrating potent in vitro efficacy with an IC₅₀ in the nanomolar range. CX08005 is soluble in DMSO and demonstrates metabolic stability in liver microsomes, making it a promising candidate for pharmacokinetic studies and early-stage drug development in oncology.

Chemical Structure

CX08005

CAS#1256341-22-6

Theoretical Analysis

MedKoo Cat#: 563748

Name: CX08005

CAS#: 1256341-22-6

Chemical Formula: C28H39NO4

Exact Mass: 453.2879

Molecular Weight: 453.62

Elemental Analysis: C, 74.14; H, 8.67; N, 3.09; O, 14.11

Price and Availability

Size	Price	Availability
25mg	USD 250.00	2 Weeks
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,650.00	2 Weeks
1g	USD 3,950.00	2 Weeks
2g	USD 5,850.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

CX08005; CX-08005; CX 08005;

IUPAC/Chemical Name

N-(2-Tetradecyloxy-phenyl)-phthalamic acid

InChi Key

WOEDXTWDPRNPMZ-UHFFFAOYSA-N

InChi Code

InChI=1S/C28H39NO4/c1-2-3-4-5-6-7-8-9-10-11-12-17-22-33-26-21-16-15-20-25(26)29-27(30)23-18-13-14-19-24(23)28(31)32/h13-16,18-21H,2-12,17,22H2,1H3,(H,29,30)(H,31,32)

SMILES Code

O=C(O)C1=CC=CC=C1C(NC2=CC=CC=C2OCCCCCCCCCCCCCC)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

CX08005 is a competitive PTP1B inhibitor (IC50 = 0.781 μM).

In vitro activity:

CX08005 exhibited remarkable dose‐dependent inhibitory activity against PTP1B with an IC50 of 7.81 × 10−7 M (Figure 1B). Reference: Br J Pharmacol. 2016 Jun; 173(12): 1939–1949. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882499/.

In vivo activity:

CX08005 was tested in KKAy mice, which is a genetic model of T2DM. KKAy mice exhibited a higher level of glucose and insulin in response to the GTT. The two parameters were much higher in KKAy mice than in control mice in GTT (Figure 4A–D). After CX08005 treatment, GTT was improved significantly with 37.0% decrease in AUCglucose (Figure 4B). Reference: Br J Pharmacol. 2016 Jun; 173(12): 1939–1949. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882499/.

	Solvent	mg/mL	mM
Solubility
	DMSO	45.4	100.00
	Ethanol	45.4	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 453.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Zhang X, Tian J, Li J, Huang L, Wu S, Liang W, Zhong L, Ye J, Ye F. A novel protein tyrosine phosphatase 1B inhibitor with therapeutic potential for insulin resistance. Br J Pharmacol. 2016 Jun;173(12):1939-49. doi: 10.1111/bph.13483. Epub 2016 May 4. PMID: 26990621; PMCID: PMC4882499.

In vitro protocol:

In vivo protocol:

1: Zhang X, Tian J, Li J, Huang L, Wu S, Liang W, Zhong L, Ye J, Ye F. A novel protein tyrosine phosphatase 1B inhibitor with therapeutic potential for insulin resistance. Br J Pharmacol. 2016 Jun;173(12):1939-49. doi: 10.1111/bph.13483. Epub 2016 May 4. PubMed PMID: 26990621; PubMed Central PMCID: PMC4882499. Qiu J, Bosch MA, Zhang C, Rønnekleiv OK, Kelly MJ. Estradiol Protects Neuropeptide Y/Agouti-Related Peptide Neurons against Insulin Resistance in Females. Neuroendocrinology. 2020;110(1-2):105-118. doi: 10.1159/000501560. Epub 2019 Jun 19. PMID: 31212279; PMCID: PMC6920578. Li J, Zhang X, Tian J, Li J, Li X, Wu S, Liu Y, Han J, Ye F. CX08005, a Protein Tyrosine Phosphatase 1B Inhibitor, Attenuated Hepatic Lipid Accumulation and Microcirculation Dysfunction Associated with Nonalcoholic Fatty Liver Disease. Pharmaceuticals (Basel). 2023 Jan 11;16(1):106. doi: 10.3390/ph16010106. PMID: 36678603; PMCID: PMC9863901.